Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CV8102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CV8102 | EXPERIMENTAL | - |
| Rabipur | ACTIVE_COMPARATOR | - |
| CV8102 + Rabipur | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CV8102 | BIOLOGICAL | Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart |
| Rabipur | BIOLOGICAL | Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart |
| CV8102 + Rabipur | BIOLOGICAL | Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart |
Inclusion Criteria: 1. Compliant with protocol procedures and available for clinical F/U until the protocol-defined end of the trial 2. Physical examination and laboratory results without clinically significant findings 3. Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 4. Subjects must use reliable ...
CV8102 is an investigational monoclonal antibody being studied for use in rabies. It is currently in Phase 1 clinical development, with one completed trial in healthy adults. The drug is being developed by BioNTech SE (BNTX).
CV8102 is being developed by BioNTech SE, a biotechnology company traded on the NASDAQ under the ticker BNTX. The drug is an investigational monoclonal antibody for rabies and is currently in Phase 1 clinical development.
CV8102 is in Phase 1 clinical development. It has completed one Phase 1 trial, and there are no active trials currently ongoing. The drug is investigational and has not been approved for any use.
CV8102 has been studied in one clinical trial, NCT02238756, titled 'Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults.' This Phase 1 trial was completed and enrolled 72 healthy male participants in Germany.
Yes, CV8102 is a monoclonal antibody. It is being investigated for the prevention or treatment of rabies. The drug is in Phase 1 clinical development, with one completed trial assessing its safety and tolerability in healthy adults.